Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2562)	11/26/2005 1:39:05 PM
From: tuck	Respond to of 3044

[Tumor Lysis Syndrome After Bortezomib Therapy for Plasma Cell Leukemia] >>Pharmacotherapy. 2005 Winter;25(12):1820-1825. Tumor Lysis Syndrome After Bortezomib Therapy for Plasma Cell Leukemia. Jaskiewicz AD, Herrington JD, Wong L. 1. Departments of Pharmacy Scott and White Memorial Hospital and Clinic, Temple, Texas. Tumor lysis syndrome (TLS) is a manifestation of metabolic disturbances that can lead to severe treatment complications and ultimately life-threatening events. This syndrome has been reported in solid tumors but is more common in bulky, hyperproliferative malignancies. Tumor lysis syndrome in plasma cell malignancies is less common due to the low turnover rate of the malignant B cells. Bortezomib is the first proteasome inhibitor approved by the United States Food and Drug Administration as second- and third-line therapy for patients with relapsed multiple myeloma. We describe the case of a patient with plasma cell leukemia treated with bortezomib who developed TLS. Bortezomib was begun as single-agent therapy that resulted in the development of TLS after the third dose of the first cycle. Evaluation with the Naranjo Adverse Drug Reaction Probability Scale indicated a probable relationship between TLS and bortezomib in this patient. Patients receiving bortezomib may be at risk for TLS, especially if they have high tumor burden, rapidly proliferative disease, and unfavorable cytogenetics.<< Not sure what the authors mean by "unfavorable cytogenetics" or if that can be quantified or tested prior to treatment. I'd guess that MLNM R&D folks would be all over the issue, pharmacogenomics being such a big deal to them. Cheers, Tuck